Progress towards a glycoconjugate vaccine against Group A Streptococcus

Autor: Keira Burns, Helge C. Dorfmueller, Brendan W. Wren, Fatme Mawas, Helen A. Shaw

Publikováno v: npj Vaccines, Vol 8, Iss 1, Pp 1-10 (2023)

Abstract The Group A Carbohydrate (GAC) is a defining feature of Group A Streptococcus (Strep A) or Streptococcus pyogenes. It is a conserved and simple polysaccharide, comprising a rhamnose backbone and GlcNAc side chains, further decorated with gly

Externí odkaz: https://doaj.org/article/4a853855392a45c3981d9cd12eabe8f9

GMMA as an Alternative Carrier for a Glycoconjugate Vaccine against Group A Streptococcus

Autor: Elena Palmieri, Zoltán Kis, James Ozanne, Roberta Di Benedetto, Beatrice Ricchetti, Luisa Massai, Martina Carducci, Davide Oldrini, Gianmarco Gasperini, Maria Grazia Aruta, Omar Rossi, Cleo Kontoravdi, Nilay Shah, Fatme Mawas, Francesca Micoli

Publikováno v: Vaccines, Vol 10, Iss 7, p 1034 (2022)

Group A Streptococcus (GAS) causes about 500,000 annual deaths globally, and no vaccines are currently available. The Group A Carbohydrate (GAC), conserved across all GAS serotypes, conjugated to an appropriate carrier protein, represents a promising

Externí odkaz: https://doaj.org/article/51ad062515b741b4afe2d444e2ee2b4a

Sublingual immunisation with GBS serotype III capsular polysaccharide-tetanus toxoid conjugate vaccine induces systemic and mucosal antibody responses which are opsonophagocytic and inhibit GBS colonisation of vaginal epithelial cells

Autor: Mohamed Deifallah Yousif, Arif Felek, Manolya Saydam, Seanette Wilson, Sudaxshina Murdan, Fatme Mawas

Publikováno v: Vaccine. 40(42)

No vaccines are currently licensed against Group B streptococcus (GBS), an important cause of morbidity and mortality in babies and adults. Using a mouse model, and in vitro opsonophagocytosis and colonisation assays, we evaluated the potential of a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d91d45d75d2c9b7ce7f4fea8cd289b2
https://pubmed.ncbi.nlm.nih.gov/36096970

Impact of routine vaccination against Haemophilus influenzae type b in The Gambia: 20 years after its introduction

Autor: Buntung Ceesay, Magnus Ochoge, Rasheed Salaudeen, Malick Ndiaye, Ousman Secka, Ilias Hossain, Saffiatou Darboe, Stephen R. C. Howie, Fatme Mawas, Richard Mihigo, Kalifa Bojang, Grant A. Mackenzie, Samba Ceesay, M Jahangir Hossain, Mary Agócs, Jason M. Mwenda, Alasana Bah, Kim Mulholland, Ignatius Baldeh, Syed M. A. Zaman, Dawda Sowe, Brenda Kwambana-Adams, Adam L. Cohen, Catherine Okoi, Christian Bottomley, Siaka Badjie, Bakary Sanneh, Haddy Bah Camara, Martin Antonio, Lamin Ceesay

Publikováno v: Journal of Global Health. 10

Background In 1997, The Gambia introduced three primary doses of Haemophilus influenzae type b (Hib) conjugate vaccine without a booster in its infant immunisation programme along with establishment of a population-based surveillance on Hib meningiti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::72fa0d696e6846c3c194f459abf2148f
https://doi.org/10.7189/jogh.10.010416

Chitosan nanoparticle antigen uptake in epithelial monolayers can predict mucosal but not systemic in vivo immune response by oral delivery

Autor: Hannah Cole, Lorna Lancaster, Fatme Mawas, Donna Bryan, Driton Vllasaliu

Publikováno v: Cole, H, Bryan, D, Lancaster, L, Mawas, F & Vllasaliu, D 2018, ' Chitosan nanoparticle antigen uptake in epithelial monolayers can predict mucosal but not systemic in vivo immune response by oral delivery ', CARBOHYDRATE POLYMERS . https://doi.org/10.1016/j.carbpol.2018.02.084

This study compared in vitro and in vivo antigen delivery effects of ultrapure chitosan (CS) chloride. CS nanoparticles were formulated to incorporate ovalbumin (OVA) as a model antigen and characterised for size, charge, OVA complexation and release

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df62021a406e9df777f4d10094bbef62